Skip to content

Nasdaq · CIK 0001506983

GCTK Glucotrack, Inc.

Insider trading from SEC Form 4. Last filing Oct 7, 2025.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company

Signals

Open-market buys and sells at Glucotrack, Inc., scored.

No scored open-market trades yet. Grants, exercises and other rows are below.

Transactions

The last 74 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Mar 25, 2025Paul Goode
Chief Executive Officer
JOther
Common Stock, par value $0.001 per share
+42--339Oct 7, 2025
Mar 25, 2025Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+35$0.00$02,395Oct 7, 2025
Mar 25, 2025Erin Catherine Carter
director
AGrant or award
Common Stock, par value $0.001 per share
+32$0.00$0762Oct 7, 2025
Mar 25, 2025Andrew K Balo
director
AGrant or award
Common Stock, par value $0.001 per share
+75$0.00$075Oct 7, 2025
Jul 11, 2025Andrew K Balo
director
AGrant or award
Common Stock, par value $0.001 per share
+3,332$0.00$03,407Oct 7, 2025
Jul 11, 2025Erin Catherine Carter
director
AGrant or award
Common Stock, par value $0.001 per share
+1,000$0.00$01,762Oct 7, 2025
Jul 11, 2025Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+1,200$0.00$03,595Oct 7, 2025
Oct 3, 2025Erin Catherine Carter
director
AGrant or award
Common Stock, par value $0.001 per share
+386$0.00$02,148Oct 7, 2025
Oct 3, 2025Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+463$0.00$04,058Oct 7, 2025
Oct 3, 2025Andrew K Balo
director
AGrant or award
Common Stock, par value $0.001 per share
+1,285$0.00$04,692Oct 7, 2025
Oct 3, 2025Andrew K Balo
director
AGrant or award
Stock option (right to buy)derivative
+4,055$0.00$04,055Oct 7, 2025
Oct 3, 2025Luis Malave
director
AGrant or award
Stock option (right to buy)derivative
+4,055$0.00$04,055Oct 7, 2025
Oct 3, 2025Erin Catherine Carter
director
AGrant or award
Stock option (right to buy)derivative
+4,055$0.00$04,055Oct 7, 2025
Nov 14, 2024John A. Ballantyne Revocable Living Trust dated 08/01/2017
owner
JOther
Common Stock, par value $0.001 per share
+132,036$31.00$4.1M183,039Mar 31, 2025
Sep 30, 2021Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+8$0.00$08Mar 31, 2025
Nov 14, 2024John Ballantyne
director, owner
JOther
Common Stock, par value $0.001 per shareindirect: John A. Ballantyne Rev Trust 08/01/2017
+132,036$31.00$4.1M183,039Mar 31, 2025
Dec 31, 2023Erin Catherine Carter
director
AGrant or award
Common Stock, par value $0.001 per share
+903$0.00$0903Mar 31, 2025
Mar 12, 2025John A. Ballantyne Revocable Living Trust dated 08/01/2017
owner
XIn-the-money exercise
Common Stock, par value $0.001 per share
+2,560,553$0.00$02,743,591Mar 31, 2025
Apr 8, 2024Erin Catherine Carter
director
AGrant or award
Common Stock, par value $0.001 per share
+458$0.00$01,361Mar 31, 2025
Mar 12, 2025John Ballantyne
director, owner
XIn-the-money exercise
Common Stock, par value $0.001 per shareindirect: John A. Ballantyne Rev Trust 08/01/2017
+2,560,553$0.00$02,743,591Mar 31, 2025
Dec 31, 2021Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+11$0.00$019Mar 31, 2025
Nov 14, 2024Erin Catherine Carter
director
CConversion
Common Stock, par value $0.001 per share
+2,078$31.20$65k3,439Mar 31, 2025
Jul 30, 2024John A. Ballantyne Revocable Living Trust dated 08/01/2017
owner
POpen-market purchase
Warrants to Purchase Common Stockderivative
+106,667--106,667Mar 31, 2025
Mar 26, 2025John Ballantyne
director, owner
AGrant or award
Common Stock, par value $0.001 per share
+4,126$0.00$04,126Mar 31, 2025
Mar 31, 2022Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+25$0.00$044Mar 31, 2025
Jun 30, 2022Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+34$0.00$078Mar 31, 2025
Jul 30, 2024John Ballantyne
director, owner
POpen-market purchase
Warrants to Purchase Common Stockderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017
+106,667--106,667Mar 31, 2025
Mar 12, 2025Erin Catherine Carter
director
XIn-the-money exercise
Common Stock, par value $0.001 per share
+40,297$0.00$043,736Mar 31, 2025
Jul 30, 2024John A. Ballantyne Revocable Living Trust dated 08/01/2017
owner
POpen-market purchase
Warrants to Purchase Common Stockderivative
+76,191--76,191Mar 31, 2025
Jul 30, 2024John A. Ballantyne Revocable Living Trust dated 08/01/2017
owner
POpen-market purchase
Warrants to Purchase Common Stockderivative
+59,260--59,260Mar 31, 2025
Mar 26, 2025Erin Catherine Carter
director
AGrant or award
Common Stock, par value $0.001 per share
+1,896$0.00$045,632Mar 31, 2025
Oct 4, 2022Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+44$0.00$0122Mar 31, 2025
Jul 30, 2024John Ballantyne
director, owner
POpen-market purchase
Warrants to Purchase Common Stockderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017
+76,191--76,191Mar 31, 2025
Nov 14, 2024John A. Ballantyne Revocable Living Trust dated 08/01/2017
owner
AGrant or award
Series A Common Warrantderivative
+132,036--132,036Mar 31, 2025
Jul 30, 2024John Ballantyne
director, owner
POpen-market purchase
Warrants to Purchase Common Stockderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017
+59,260--59,260Mar 31, 2025
Jan 9, 2023Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+29$0.00$0151Mar 31, 2025
Jul 18, 2024Erin Catherine Carter
director
POpen-market purchase
Convertible Promissory Notederivative
-$50,000.00--Mar 31, 2025
Nov 14, 2024Erin Catherine Carter
director
CConversion
Convertible Promissory Notederivative
-$64,831.00-0Mar 31, 2025
Apr 20, 2023Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+121$0.00$0272Mar 31, 2025
Nov 14, 2024John Ballantyne
director, owner
AGrant or award
Series A Common Warrantderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017
+132,036--132,036Mar 31, 2025
Nov 14, 2024John A. Ballantyne Revocable Living Trust dated 08/01/2017
owner
AGrant or award
Series B Common Warrantderivative
+132,036--132,036Mar 31, 2025
Nov 14, 2024Erin Catherine Carter
director
AGrant or award
Series A Common Warrantderivative
+2,078--2,078Mar 31, 2025
Dec 31, 2023Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+362$0.00$0634Mar 31, 2025
Nov 14, 2024John Ballantyne
director, owner
AGrant or award
Series B Common Warrantderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017
+132,036--132,036Mar 31, 2025
Mar 12, 2025John A. Ballantyne Revocable Living Trust dated 08/01/2017
owner
XIn-the-money exercise
Series B Common Warrantderivative
-132,036$0.00$00Mar 31, 2025
Mar 12, 2025John Ballantyne
director, owner
XIn-the-money exercise
Series B Common Warrantderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017
-132,036$0.00$00Mar 31, 2025
Apr 8, 2024Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+489$0.00$01,123Mar 31, 2025
Nov 14, 2024Erin Catherine Carter
director
AGrant or award
Series B Common Warrantderivative
+2,078--2,078Mar 31, 2025
Nov 14, 2024Luis Malave
director
CConversion
Common Stock, par value $0.001 per share
+6,886$31.20$215k8,009Mar 31, 2025
Mar 12, 2025Erin Catherine Carter
director
XIn-the-money exercise
Series B Common Warrantderivative
-2,078$0.00$00Mar 31, 2025
Mar 12, 2025Luis Malave
director
XIn-the-money exercise
Common Stock, par value $0.001 per share
+133,532$0.00$0141,541Mar 31, 2025
Mar 26, 2025Luis Malave
director
AGrant or award
Common Stock, par value $0.001 per share
+2,076$0.00$0143,617Mar 31, 2025
Jul 18, 2024Luis Malave
director
POpen-market purchase
Convertible Promissory Notederivative
-$200,000.00--Mar 31, 2025
Nov 14, 2024Luis Malave
director
CConversion
Convertible Promissory Notederivative
-$214,831.00-0Mar 31, 2025
Nov 14, 2024Luis Malave
director
AGrant or award
Series A Common Warrantderivative
+6,886--6,886Mar 31, 2025
Nov 14, 2024Luis Malave
director
AGrant or award
Series B Common Warrantderivative
+6,886--6,886Mar 31, 2025
Mar 12, 2025Luis Malave
director
XIn-the-money exercise
Series B Common Warrantderivative
-6,886$0.00$00Mar 31, 2025
Oct 4, 2022Allen Danzig
director
AGrant or award
Common Stock, par value $0.001 per share
+44$0.00$0195Mar 28, 2025
Aug 24, 2021Robert Fischell
director
AGrant or award
Common Stock, par value $0.001 per share
+318$0.00$0318Mar 28, 2025
Nov 14, 2024Paul Goode
Chief Executive Officer
CConversion
Common Stock, par value $0.001 per share
+796$31.20$25k2,054Mar 28, 2025
Mar 26, 2025Andrew K Balo
director
AGrant or award
Common Stock, par value $0.001 per share
+4,490$0.00$04,490Mar 28, 2025
Apr 8, 2024Allen Danzig
director
AGrant or award
Common Stock, par value $0.001 per share
+229$0.00$0424Mar 28, 2025
Apr 8, 2024Robert Fischell
director
AGrant or award
Common Stock, par value $0.001 per share
+229$0.00$0547Mar 28, 2025
Feb 5, 2025Paul Goode
Chief Executive Officer
JOther
Common Stock, par value $0.001 per share
+1,500--3,554Mar 28, 2025
Mar 12, 2025Paul Goode
Chief Executive Officer
XIn-the-money exercise
Common Stock, par value $0.001 per share
+15,435$0.00$018,989Mar 28, 2025
Mar 26, 2025Robert Fischell
director
AGrant or award
Common Stock, par value $0.001 per share
+1,498$0.00$02,045Mar 28, 2025
Mar 26, 2025Allen Danzig
director
AGrant or award
Common Stock, par value $0.001 per share
+1,498$0.00$01,922Mar 28, 2025
Jun 14, 2024Paul Goode
Chief Executive Officer
AGrant or award
Stock option (right to buy)derivative
+3,277$0.00$03,277Mar 28, 2025
Jul 1, 2024Paul Goode
Chief Executive Officer
POpen-market purchase
Warrants to Purchase Common Stockderivative
+2,100--2,100Mar 28, 2025
Jul 18, 2024Paul Goode
Chief Executive Officer
POpen-market purchase
Convertible Promissory Notederivative
-$10,000.00--Mar 28, 2025
Nov 14, 2024Paul Goode
Chief Executive Officer
CConversion
Convertible Promissory Notederivative
-$24,831.00--Mar 28, 2025
Nov 14, 2024Paul Goode
Chief Executive Officer
AGrant or award
Series A Common Warrantderivative
+796--796Mar 28, 2025
Nov 14, 2024Paul Goode
Chief Executive Officer
AGrant or award
Series B Common Warrantderivative
+796--796Mar 28, 2025
Mar 12, 2025Paul Goode
Chief Executive Officer
XIn-the-money exercise
Series B Common Warrantderivative
+796$0.00$00Mar 28, 2025

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

GCTK insider trading: Glucotrack, Inc. | InsiderTell